FP agonizts effectively reduce IOP by enhancing the uveoscleral outflow of aqueous humor and offer a convenient once-daily dosing schedule.6 However, not all patients with POAG respond to FP agonizts and these agents have the potential to cause adverse ocular effects. The gene discussed is PTGFR; the disease is open-angle glaucoma.